Mylan NV (MYL.OQ)
37.81USD
12:09pm EDT
$0.60 (+1.61%)
$37.21
$37.19
$37.86
$37.10
376,717
1,356,165
$47.81
$30.69
About
Overall
| Beta: | 1.44 |
| Market Cap(Mil.): | $19,184.26 |
| Shares Outstanding(Mil.): | 515.57 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MYL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 33.78 | 29.91 | 32.14 |
| EPS (TTM): | 1.10 | -- | -- |
| ROI: | 1.99 | 12.97 | 12.66 |
| ROE: | 4.68 | 14.97 | 14.84 |
BRIEF-Mylan Closes Deal With Novartis To Commercialize Certain Global Cystic Fibrosis Products
* MYLAN - CLOSED DEAL WITH NOVARTIS TO BUY WORLDWIDE RIGHTS TO COMMERCIALIZE GLOBAL CYSTIC FIBROSIS PRODUCTS CONSISTING OF TOBI PODHALER & TOBI SOLUTION Source text for Eikon: (https://bit.ly/2oJcNd7) Further company coverage:
Mylan, Pfizer must face consumer lawsuit over EpiPen: judge
A federal judge has rejected Mylan NV's bid to escape a proposed class action lawsuit accusing the drugmaker of engaging in an unlawful scheme to squelch competition for its EpiPen allergy treatment, allowing it to unjustifiably raise its prices.
FDA extends EpiPen expiry date to combat shortage
The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.
U.S. FDA extends EpiPen expiry date to combat shortage
Aug 21 The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.
FDA approves Teva's generic of Mylan's EpiPen
The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs. | Video
UPDATE 2-U.S. FDA approves Teva's generic of Mylan's EpiPen
Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs.
U.S. FDA approves first generic version of Mylan's EpiPen
Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's EpiPen for the emergency treatment of allergic reactions.
Wall Street dragged down by fall out from Turkey's plunging lira
NEW YORK U.S. stocks dropped on Monday as global jitters from Turkey's plummeting currency spread to Wall Street, with the S&P 500 and the Dow falling for the fourth session in a row. | Video
Mylan eyes 'all alternatives' as quarterly profit falls short
Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.
UPDATE 4-Mylan eyes 'all alternatives' as quarterly profit falls short
Aug 8 Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.
Estimates